Conatus Pharmaceuticals Inc. (CNAT) Reaches $5.06 After 9.00% Down Move; Bbr Partners Lowered Its Ellington Financial (EFC) Position

February 14, 2018 - By Louis Casey

The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) is a huge mover today! The stock decreased 1.56% or $0.08 during the last trading session, reaching $5.06. About 235,344 shares traded. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has risen 140.55% since February 14, 2017 and is uptrending. It has outperformed by 123.85% the S&P500.The move comes after 6 months negative chart setup for the $151.83 million company. It was reported on Feb, 14 by Barchart.com. We have $4.60 PT which if reached, will make NASDAQ:CNAT worth $13.66 million less.

Bbr Partners Llc decreased Ellington Financial Llc (EFC) stake by 6.64% reported in 2017Q3 SEC filing. Bbr Partners Llc sold 58,950 shares as Ellington Financial Llc (EFC)’s stock rose 5.48%. The Bbr Partners Llc holds 828,757 shares with $13.09M value, down from 887,707 last quarter. Ellington Financial Llc now has $479.52 million valuation. The stock increased 0.47% or $0.07 during the last trading session, reaching $14.93. About 39,523 shares traded. Ellington Financial LLC (NYSE:EFC) has declined 3.64% since February 14, 2017 and is downtrending. It has underperformed by 20.34% the S&P500.

Investors sentiment decreased to 1.83 in 2017 Q3. Its down 1.94, from 3.77 in 2017Q2. It is negative, as 9 investors sold Conatus Pharmaceuticals Inc. shares while 14 reduced holdings. 21 funds opened positions while 21 raised stakes. 10.89 million shares or 43.42% less from 19.24 million shares in 2017Q2 were reported. Qs Ltd Llc has 0% invested in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Deutsche Retail Bank Ag holds 0% or 130,558 shares in its portfolio. Axa has invested 0.01% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Renaissance Technology Ltd Com invested 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). The New York-based Grp has invested 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). State Of Wisconsin Invest Board invested in 0% or 20,000 shares. Citadel Advsr Limited Liability Company accumulated 0% or 39,726 shares. Courage Management Ltd Liability has 0.73% invested in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Wellington Mgmt Group Llp stated it has 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Tiaa Cref Ltd Company holds 0% or 168,703 shares. New York State Common Retirement Fund accumulated 0% or 24,100 shares. Arrowstreet L P has 106,000 shares. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Eam Invsts Limited invested in 62,752 shares or 0.05% of the stock. Moreover, Aqr Capital Mngmt has 0% invested in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT).

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. The company has market cap of $151.83 million. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. It currently has negative earnings.

Among 5 analysts covering Conatus Pharma (NASDAQ:CNAT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Conatus Pharma had 11 analyst reports since September 22, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, November 5 by Stifel Nicolaus. On Friday, July 1 the stock rating was initiated by Roth Capital with “Buy”. Stifel Nicolaus maintained the shares of CNAT in report on Tuesday, December 20 with “Buy” rating. The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has “Buy” rating given on Wednesday, November 9 by Stifel Nicolaus. The firm has “Buy” rating given on Tuesday, September 22 by H.C. Wainwright. Stifel Nicolaus maintained Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) on Thursday, August 3 with “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $18 target in Tuesday, December 20 report. H.C. Wainwright maintained Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) rating on Thursday, June 29. H.C. Wainwright has “Buy” rating and $1800 target.

Analysts await Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to report earnings on March, 21. They expect $-0.17 EPS, up 51.43% or $0.18 from last year’s $-0.35 per share. After $-0.13 actual EPS reported by Conatus Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 30.77% negative EPS growth.

Among 7 analysts covering Ellington Financial (NYSE:EFC), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Ellington Financial had 20 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, February 18 by Maxim Group. The rating was maintained by Maxim Group on Monday, October 9 with “Buy”. The firm earned “Buy” rating on Tuesday, January 9 by Maxim Group. The stock has “Outperform” rating by FBR Capital on Friday, February 24. As per Tuesday, September 12, the company rating was maintained by Keefe Bruyette & Woods. The firm has “Buy” rating by Maxim Group given on Tuesday, July 11. As per Thursday, August 13, the company rating was maintained by Maxim Group. The firm has “Buy” rating given on Monday, November 9 by Deutsche Bank. Sandler O’Neill initiated it with “Buy” rating and $17 target in Wednesday, December 6 report. On Tuesday, October 11 the stock rating was maintained by Maxim Group with “Buy”.

Investors sentiment decreased to 0.64 in 2017 Q3. Its down 1.00, from 1.64 in 2017Q2. It dived, as 10 investors sold EFC shares while 15 reduced holdings. 4 funds opened positions while 12 raised stakes. 13.85 million shares or 8.66% less from 15.16 million shares in 2017Q2 were reported. Raymond James & Associates holds 13,446 shares. 16,970 were accumulated by Wells Fargo And Mn. Tahithromos Ltd Limited Liability Company, a New York-based fund reported 140,189 shares. Morgan Stanley holds 0% or 381,858 shares in its portfolio. Glenmede Tru Na holds 0% of its portfolio in Ellington Financial LLC (NYSE:EFC) for 22 shares. Bank Of America Corp De has invested 0% in Ellington Financial LLC (NYSE:EFC). Moreover, Omega Advsr has 0.04% invested in Ellington Financial LLC (NYSE:EFC). Merriman Wealth Management Limited Company holds 1.22% of its portfolio in Ellington Financial LLC (NYSE:EFC) for 325,941 shares. Two Sigma Securities Limited Company has invested 0.02% in Ellington Financial LLC (NYSE:EFC). Wellington Management Group Llp holds 3.47M shares or 0.01% of its portfolio. Endowment Mgmt Ltd Partnership holds 20,000 shares or 0.04% of its portfolio. Bbr Lc holds 2.79% or 828,757 shares in its portfolio. Royal National Bank Of Canada reported 8,611 shares. Bb&T Securities Limited Liability Corporation accumulated 0.01% or 57,249 shares. Optimum Invest Advsrs reported 13,015 shares or 0.07% of all its holdings.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>